🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: VI 100 mcg

Found 38 matching trials

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

PHASE4

This is a multi-center, randomized, double-blind, parallel-group study. The...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-01-28

Trial ID

NCT01957150

Treatments Being Tested

Fluticasone Furoate/Vilanterol Vilanterol

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

PHASE3

This is a Phase III, multicenter, randomized, double-blind, stratified, par...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-09-20

Trial ID

NCT01686633

Treatments Being Tested

Fluticasone Furoate/ Vilanterol 200/25 mcg Fluticasone Furoate/ Vilanterol 100/25 mcg Fluticasone Furoate 100 mcg

Relovair PD PK in Chinese Healthy Subjects

PHASE1

In this study, fluticasone furoate (FF) and vilanterol (VI) in different do...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-12-05

Trial ID

NCT01711463

Treatments Being Tested

Fluticasone Furoate/Vilanterol Placebo

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

PHASE3

After screening, subjects will enter a 4 week open-label run-in period with...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-10

Trial ID

NCT02119286

Treatments Being Tested

FF VI UMEC Placebo

Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic

Background: Up-to-date, there is no recognized effective treatment or vacci...

Status

Completed

Location

Benha Faculty of Medicine, Benha University

Start Date

2020-06-08

Trial ID

NCT04668469

Treatments Being Tested

Ivermectin Hydroxychloroquine personal protective Measures

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

PHASE3

The goal of asthma treatment is to achieve and maintain asthma control and ...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-10-20

Trial ID

NCT03248128

Treatments Being Tested

FF/VI via ELLIPTA DPI FF via ELLIPTA DPI

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The study evaluates the efficacy of fluticasone furoate/umeclidinium bromid...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-06-30

Trial ID

NCT02164513

Treatments Being Tested

fluticasone furoate (FF)vilanterol (VI)umeclidinium bromide (UMEC)

Previous Next